Thursday , September 23 2021

Gland Pharma IPO: Expensive at a price tag of 30x the FY20 earnings

While prospects remain strong led by niche products and a differentiated business model, relatively rich valuations leave limited scope for upside in near-termWhile prospects remain strong led by niche products and a differentiated business model, relatively rich valuations leave limited scope for upside in near-termRead More

About

Check Also

Social impact venture Charitnation helps more than 25000 families of migrant and daily wage earners during Covid-19 crisis in India

New Delhi [India], September 15 (ANI/SRV Media): India was put in lockdown to halt the …

Leave a Reply

Your email address will not be published. Required fields are marked *